WallStreetZenWallStreetZen

NASDAQ: TRVI
Trevi Therapeutics Inc Stock

$2.81+0.16 (+6.04%)
Updated Jul 11, 2024
TRVI Price
$2.81
Fair Value Price
$0.31
Market Cap
$197.92M
52 Week Low
$0.97
52 Week High
$4.00
P/E
-8.26x
P/B
2.74x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$33.57M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.09
Operating Cash Flow
-$34M
Beta
0.27
Next Earnings
Aug 8, 2024
Ex-Dividend
N/A
Next Dividend
N/A

TRVI Overview

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TRVI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

TRVI ($2.81) is overvalued by 795.98% relative to our estimate of its Fair Value price of $0.31 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
TRVI ($2.81) is not significantly undervalued (795.98%) relative to our estimate of its Fair Value price of $0.31 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
TRVI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TRVI due diligence checks available for Premium users.

Be the first to know about important TRVI news, forecast changes, insider trades & much more!

TRVI News

Valuation

TRVI fair value

Fair Value of TRVI stock based on Discounted Cash Flow (DCF)
Price
$2.81
Fair Value
$0.31
Overvalued by
795.98%
TRVI ($2.81) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TRVI ($2.81) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TRVI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

TRVI price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-8.26x
Industry
-14.46x
Market
31.84x

TRVI price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.74x
Industry
6.37x
TRVI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

TRVI's financial health

Profit margin

Revenue
$0.0
Net Income
-$10.9M
Profit Margin
0%
TRVI's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$78.6M
Liabilities
$6.2M
Debt to equity
0.09
TRVI's short-term assets ($76.77M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TRVI's short-term assets ($76.77M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TRVI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TRVI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$10.5M
Investing
-$8.1M
Financing
-$28.0k
TRVI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

TRVI vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
TRVI$197.92M+6.04%-8.26x2.74x
OTLK$196.14M+10.12%-0.73x-1.46x
XBIT$202.85M+6.22%-6.53x0.97x
GLSI$203.25M+0.06%-21.92x39.69x
STTK$192.58M+9.46%-2.10x1.50x

Trevi Therapeutics Stock FAQ

What is Trevi Therapeutics's quote symbol?

(NASDAQ: TRVI) Trevi Therapeutics trades on the NASDAQ under the ticker symbol TRVI. Trevi Therapeutics stock quotes can also be displayed as NASDAQ: TRVI.

If you're new to stock investing, here's how to buy Trevi Therapeutics stock.

What is the 52 week high and low for Trevi Therapeutics (NASDAQ: TRVI)?

(NASDAQ: TRVI) Trevi Therapeutics's 52-week high was $4.00, and its 52-week low was $0.97. It is currently -29.75% from its 52-week high and 189.69% from its 52-week low.

How much is Trevi Therapeutics stock worth today?

(NASDAQ: TRVI) Trevi Therapeutics currently has 70,435,093 outstanding shares. With Trevi Therapeutics stock trading at $2.81 per share, the total value of Trevi Therapeutics stock (market capitalization) is $197.92M.

Trevi Therapeutics stock was originally listed at a price of $7.89 in May 7, 2019. If you had invested in Trevi Therapeutics stock at $7.89, your return over the last 5 years would have been -64.39%, for an annualized return of -18.66% (not including any dividends or dividend reinvestments).

How much is Trevi Therapeutics's stock price per share?

(NASDAQ: TRVI) Trevi Therapeutics stock price per share is $2.81 today (as of Jul 11, 2024).

What is Trevi Therapeutics's Market Cap?

(NASDAQ: TRVI) Trevi Therapeutics's market cap is $197.92M, as of Jul 12, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Trevi Therapeutics's market cap is calculated by multiplying TRVI's current stock price of $2.81 by TRVI's total outstanding shares of 70,435,093.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.